Novo Nordisk's Wegovy Pill Fuels Earnings Beat and Bullish Outlook

Novo Nordisk (NVO) delivered a massive first-quarter earnings beat, reporting sales of $15.17 billion against an expected $11.13 billion. This 32% jump was partly fueled by a one-time reversal of a U.S. drug pricing provision, but the underlying story is even stronger.

The star of the show was the newly launched Wegovy pill. Since its U.S. debut in January 2026, it has seen "rapid uptake," with weekly prescriptions exceeding 200,000 by mid-April. The pill racked up about 1.3 million scripts in Q1 alone and over 2 million since launch, indicating powerful initial demand.

Beyond the pill, Novo's established GLP-1 franchise remains robust. Sales of the injectable Wegovy grew 26%, while diabetes drug Ozempic saw sales jump 32%. This demonstrates the company's ability to grow both its flagship products simultaneously.

Bolstered by this performance, management raised its full-year 2026 sales guidance. The new range is $42.39 billion to $46.24 billion, up from the previous forecast of $40.46 billion to $44.32 billion, showing increased confidence in the year ahead.

The stock reacted positively in pre-market trading, reflecting investor approval of the strong results and upgraded outlook.

This quarter matters because it proves Novo Nordisk isn't a one-trick pony reliant solely on injectable drugs. The successful launch of the Wegovy pill opens a massive new front in the weight-loss market, appealing to patients who prefer oral medication over injections.

The pill's fast prescription growth suggests Novo is effectively capturing new market segments and expanding its total addressable market. With international launches planned for late 2026 pending approvals, this growth story has significant runway beyond the U.S.

Financially, the raised guidance directly translates to higher expected future earnings, which is a primary driver of stock valuation. It signals to investors that management's bullish view on demand is concrete, not just hopeful.

In the high-stakes battle with Eli Lilly (LLY), this performance strengthens Novo's competitive moat. Demonstrating it can innovate (with the pill) and execute (with strong Ozempic/Wegovy injectable sales) simultaneously is a powerful combination that justifies its premium valuation.

For the broader market, Novo's success reinforces the immense and seemingly insatiable demand for GLP-1 therapies, validating the entire sector's growth narrative and putting pressure on competitors to keep pace.